(19)
(11) EP 4 240 406 A1

(12)

(43) Date of publication:
13.09.2023 Bulletin 2023/37

(21) Application number: 21816264.2

(22) Date of filing: 05.11.2021
(51) International Patent Classification (IPC): 
A61K 39/00(2006.01)
C07K 16/28(2006.01)
A61P 35/02(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/2809; C07K 16/2803; C07K 2317/73; C07K 2317/31; A61P 35/02; C07K 16/2818; C07K 2317/76; C07K 2317/24; A61K 2039/505; A61K 2039/507; C07K 2317/626; C07K 2317/75
(86) International application number:
PCT/US2021/058254
(87) International publication number:
WO 2022/099006 (12.05.2022 Gazette 2022/19)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 05.11.2020 US 202063110011 P

(71) Applicant: Anji Bruno, LLC
Cambridge, MA 02142 (US)

(72) Inventors:
  • SMITH, Victoria
    South San Francisco, California 94080 (US)
  • SARDE, Aurelien
    Palo Alto, California 94306 (US)

(74) Representative: HGF 
HGF Limited 1 City Walk
Leeds LS11 9DX
Leeds LS11 9DX (GB)

   


(54) ASSESSMENT OF CANCERS FOR TREATMENT WITH A CD33/CD3 BISPECIFIC T CELL ENGAGER